This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Digging into the topline data from Iveric Bio's Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy and how it compares to Apellis' EMPAVELI

Ticker(s): ISEE, APLS

Who's the expert?

Institution: Private practice

  • Pediatric & Adult Retina Specialist; treats 15-20 patients a week with Geographic Atrophy.
  • Clinical and research interests include retinopathy of prematurity, Coats' disease, familial exudative vitreoretinopathy, persistent fetal vasculature, macular degeneration, diabetic retinopathy, macular holes, retinal detachments, proliferative vitreoretinopathy, and ocular trauma. 
  • Has published over 30 peer reviewed manuscripts and book chapters in internationally esteemed journals, including PNAS, Nanomedicine, Ophthalmology, Retina, and IOVS.

Interview Goal
This conversation will focus on the recent data on Zimura and how this compares with Apellis' pegcetacoplan (EMPAVELI) for patients with GA.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.